Thomas Tassin
YOU?
Author Swipe
View article: Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry Open
Measurable residual disease (MRD) is a key prognostic marker in acute myeloid leukemia (AML) but its significance in patients treated with azacitidine and venetoclax (AZA/VEN) outside clinical trials remains unclear. We retrospectively ana…
View article: Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort
Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort Open
Since 2008, the JAK2V617F mutation has been key for diagnosing myeloproliferative neoplasms (MPN) according to the World Health Organization criteria. However, the clinical and biological significance of low JAK2V617F…
View article: Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors Open
The advent of BTK inhibitors has been transformative in the management of patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders. However, emergence of BTK or PLCG2 mutations lead to resistance to these co…
View article: Near‐early T‐cell precursor acute lymphoblastic leukemia following a diagnosis of essential thrombocythemia
Near‐early T‐cell precursor acute lymphoblastic leukemia following a diagnosis of essential thrombocythemia Open
A 54-year-old man with a history of essential thrombocythemia (ET) harboring the JAK2V617F mutation (variant allele fraction [VAF], 9.7%) with normal karyotype, initially treated with interferon alpha for 5 years and then with hydroxyurea …
View article: The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia Open
RNA splicing factors are frequently altered in cancer and can act as both oncoproteins and tumour suppressors. They have been found mutated or deregulated, justifying the growing interest in the targeting of splicing catalysis, splicing re…
View article: Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
Mast cell density and its clinical relevance in Waldenström's macroglobulinemia Open
The presence of numerous mast cells (MCs) mixed with tumor cells in the bone marrow (BM) is a hallmark of the diagnosis of Waldenström's macroglobulinemia (WM). MCs have been shown to support lymphoplasmacytic cell growth, but there is thu…
View article: Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells Open